Qiliqiangxin Alleviates Imbalance of Inflammatory Cytokines in Patients with Dilated Cardiomyopathy: A Randomized Controlled Trial

Abstract

Objective

Qiliqiangxin (QLQX) capsule- a traditional Chinese medicine used for treating heart failure (HF), can modulate inflammatory cytokines in rats with myocardial infarction. However, its immune-regulating effect on dilated cardiomyopathy (DCM) remains unknown. The aim of this study was to investigate whether QLQX has a unique regulatory role in the imbalance of pro- and anti-inflammatory cytokines in patients with DCM.

Methods

The QLQX-DCM is a randomized- double-blind trial conducted at 24 tertiary hospitals in China. A total of 345 patients with newly diagnosed virus-induced DCM were randomly assigned to receive QLQX capsules or placebo while receiving optimal medical therapy for HF. The primary endpoints were changes in plasma inflammatory cytokines and improvements in left ventricular ejection fraction (LVEF) and left ventricular end-diastolic diameter (LVEDd) over the 12-month treatment.

Results

At the 12-month follow-up, the levels of IFN-γ, IL-17, TNF-α, and IL-4 decreased significantly, while the level of IL-10 increased in both groups compared with baselines (all P<0.0001). Furthermore-these changes, coupled with improvements in LVEF, NT-proBNP and New York Heart Association (NYHA) functional classification, excluding the LVEDd in the QLQX group, were greater than those in the placebo group (all P<0.001). Additionally, compared with placebo, QLQX treatment also reduced all-cause mortality and rehospitalization rates by 2.17% and 2.28%, respectively, but the difference was not statistically significant.

Conclusion

QLQX has the potential to alleviate the imbalance of inflammatory cytokines in patients with DCM, potentially leading to further improvements in cardiac function when combined with anti-HF standard medications.

References

[1] PintoYM, ElliottPM, ArbustiniE, et al.. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic nondilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J, 2016, 37(23): 1850-1858

[2] SavareseG, BecherPM, LundLH, et al.. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res, 2023, 118(17): 3272-3287

[3] SchultheissHP, FairweatherD, CaforioALP, et al.. Dilated cardiomyopathy. Nat Rev Dis Primers, 2019, 5(1): 32

[4] LappéJM, PelfreyCM, TangWH. Recent insights into the role of autoimmunity in idiopathic dilated cardiomyopathy. J Card Fail, 2008, 14(16): 521-530

[5] WangZ, LiaoY, YuanJ, et al.. Analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in anti-CD4 monoclonal antibody treated mice with autoimmune cardiomyopathy. J Huazhong Univ Sci Technolog Med Sci, 2008, 28(4): 409-414

[6] LiJ, LeschkaS, RutschowS, et al.. Immunomodulation by interleukin-4 suppresses matrix metalloproteinases and improves cardiac function in murine myocarditis. Eur J Pharmacol, 2007, 554: 60-68

[7] CihakovaD, RoseNR. Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol, 2008, 99: 95-114

[8] YuanJ, YuM, LinQW, et al.. Th17 cells contribute to viral replication in coxsackievirus B3-induced acute viral myocarditis. J Immunol, 2010, 185(7): 4004-4010

[9] YuanJ, CaoAL, YuM, et al.. Th17 cells facilitate the humoral immune response in patients with acute viral myocarditis. J Clin Immunol, 2010, 30(2): 226-234

[10] BaldevianoGC, BarinJG, TalorMV, et al.. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res, 2010, 106(10): 1646-1655

[11] YuanJ, YuM, LinQW, et al.. Neutralization of IL-17 inhibits the production of anti-ANT autoantibodies in CVB3-induced acute viral myocarditis. Int Immunopharmacol, 2010, 10(3): 272-276

[12] LiaoYH, YuanJ, WangZH, et al.. Infectious tolerance to ADP/ATP carrier peptides induced by anti-L3T4 monoclonal antibody in dilated cardiomyopathy mice. J Clin Immunol, 2005, 25(4): 376-384

[13] CacciapagliaF, NavariniL, MennaP, et al.. Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues. Autoimmun Rev, 2011, 10(10): 631-635

[14] LiX, ZhangJ, HuangJEfficacySafety of Qili Qiangxin Capsules for Chronic Heart Failure Study Group, et al.. A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol, 2013, 62(12): 1065-1072

[15] WuYL, GuCH, XuGC, et al.. Clinical observation of randomized double-blind and multicenter trial on Qiliqiangxin capsule in the treatment of chronic heart failure. Chin J Difficult Complicated Cases, 2007, 6(5): 263-266(Chinese)

[16] SunJ, ZhangK, XiongWJ, et al.. Clinical effects of a standardized Chinese herbal remedy, QiliQiangxin, as an adjuvant treatment in heart failure: systematic review and meta-analysis. BMC Complement Altern Med, 2016, 16: 201

[17] ZhangY, ZhuM, ZhangF, et al.. Integrating pharmacokinetics study, network analysis, and experimental validation to uncover the mechanism of Qiliqiangxin capsule against chronic heart failure. Front Pharmacol, 2019, 10: 1046

[18] XiaoH, SongY, LiY, et al.. Qiliqiangxin regulates the balance between tumor necrosis factor-alpha and interleukin-10 and improves cardiac function in rats with myocardial infarction. Cell Immunol, 2009, 260(1): 51-55

[19] RichardsonP, McKennaW, BristowM, et al.. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation, 1996, 93(5): 841-842

[20] CaforioAL, PankuweitS, ArbustiniEEuropean Society of Cardiology Working Group on Myocardial and Pericardial Diseases, et al.. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J, 2013, 34(33): 2636-2648 2648a-2648d

[21] WangZH, LiaoYH, YuanJ, et al.. Continued elevation of plasma IL-4 and IL-17 predicts the progression from VMC to DCM. Dis Markers, 20209385472

[22] DickSA, EpelmanS. Chronic heart failure and inflammation: what do we truly know?. Circ Res, 2016, 119(1): 159-176

[23] AdamoL, Rocha-ResendeC, PrabhuSD, et al.. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol, 2020, 17(5): 269-285

[24] Reina-CoutoM, Pereira-TerraP, Quelhas-SantosJ, et al.. Inflammation in human heart failure: major mediators and therapeutic targets. Front Physiol, 2021, 12: 746494

[25] YuM, HuJ, ZhuMX, et al.. Cardiac fibroblasts recruit Th17 cells infiltration into myocardium by secreting CCL20 in CVB3-induced acute viral myocarditis. Cell Physiol Biochem, 2013, 32(5): 1437-1450

[26] NindlV, MaierR, RateringD, et al.. Cooperation of Th1 and Th17 cells determines transition from autoimmune myocarditis to dilated cardiomyopathy. Eur J Immunol, 2012, 42(9): 2311-2321

[27] YamashitaT, IwakuraT, MatsuiK, et al.. IL-6-mediated Th17 differentiation through RORγt is essential for the initiation of experimental autoimmune myocarditis. Cardiovasc Res, 2011, 91(4): 640-648

[28] MyersJM, CooperLT, KemDC, et al.. Cardiac myosin-Th17 responses promote heart failure in human myocarditis. JCI Insight, 2016, 1(9): 85851

[29] JavedQ, MurtazaI. Therapeutic potential of tumor necrosis factor-alpha antagonists in patients with chronic heart failure. Heart Lung Circ, 2013, 22(5): 323-327

[30] HajjarRJ, LeopoldJA. Inflammation and heart failure: Friend or foe?. Circulation, 2021, 144(15): 1241-1243

[31] HofmannU, FrantzS. How can we cure a heart “in flame”? A translational view on inflammation in heart failure. Basic Res Cardiol, 2013, 108(4): 356

[32] EverettBM, CornelJH, LainscakM, et al.. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. Circulation, 2019, 139(10): 1289-1299

[33] KažukauskienėI, BaltrūnienėV, RinkūnaitėI, et al.. Inflammation-related biomarkers are associated with heart failure severity and poor clinical outcomes in patients with nonischemic dilated cardiomyopathy. Life (Basel), 2021, 11(10): 1006

[34] RidkerPM, MacFadyenJG, ThurenTCANTOS Trial Group, et al.. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomized, double-blind, placebo-controlled trial. Lancet, 2017, 390(10105): 1833-1842

[35] Chinese Society of CardiologyEditorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and treatment of chronic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi, 2014, 42(2): 98-122(Chinese)

[36] HochNE, GuzikTJ, ChenW, et al.. Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol, 2009, 296(2): R208-R216

[37] TsaiMK, JanRL, LinCH, et al.. Suppressive effects of imidapril on Th1- and Th2-related chemokines in monocytes. J Investig Med, 2011, 59(7): 1141-1146

[38] PlattenM, YoussefS, HurEM, et al.. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17- mediated autoimmunity. Proc Natl Acad Sci USA, 2009, 106(35): 14948-14953

[39] LiJ, YangP. Inhibition of periostin by Qiliqiangxin to improve ventricular remodeling in heart failure rats. Chin J Lab Diagnos, 2009, 13(2): 170-172(Chinese)

[40] ZouY, LinL, YeY, et al.. Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice. J Cardiovasc Pharmacol, 2012, 59(3): 268-280

[41] LinJ, LiQ, JinT, et al.. Cardiomyocyte IL-1R2 protects heart from ischemia/reperfusion injury by attenuating IL-17RA-mediated cardiomyocyte apoptosis. Cell Death Dis, 2022, 13(1): 90

[42] YoshidaT, DasNA, CarpenterAJ, et al.. Minocycline reverses IL-17A/TRAF3IP2-mediated p38 MAPK/NF-kappaB/iNOS/ NO-dependent cardiomyocyte contractile depression and death. Cell Signal, 2020, 73: 109690

[43] LongQ, LiL, YangH, et al.. SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis. Int Immunopharmacol, 2022, 110: 109024

[44] DinyNL, BaldevianoGC, TalorMV, et al.. Eosinophil-derived IL-4 drives progression of myocarditis to inflammatory dilated cardiomyopathy. J Exp Med, 2017, 214(4): 943-957

[45] LiQ, YeWX, HuangZJ, et al.. Effect of IL-6-mediated STAT3 signaling pathway on myocardial apoptosis in mice with dilated cardiomyopathy. Eur Rev Med Pharmacol Sci, 2019, 23(7): 3042-3050

[46] ChangHY, WangCC, WuYW, et al.. One-year outcomes of acute decompensated systolic heart failure in Taiwan: Lessons from TSOC-HFrEF Registry. Acta Cardiol Sin, 2017, 33(2): 127-138

[47] ChioncelO, LainscakM, SeferovicP, et al.. >Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail, 2017, 19(12): 1574-1585

[48] McDonaghTA, MetraM, AdamoM, et al.. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J, 2021, 42(36): 3599-3726

[49] HeidenreichPA, BozkurtB, AguilarD, et al.. 2022 AHA/ACC/ HFSA Guideline for the management of heart failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol, 2022, 79(17): e263-e421

[50] ArbeloE, ProtonotariosA, GimenoJR, et al.. ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J, 2023, 44(37): 3503-3626